Tag - CADL

Executive Moves

Candel appoints Mark Sims as CCO

Candel Therapeutics (NASDAQ: CADL) has announced the appointment of Mark Sims as its chief commercial officer (CCO), effective July 6, 2026. Mr. Sims will lead Candel’s commercial strategy and launch readiness for...

June 25, 2026

Executive Moves

Dr. Bali Pulendran joins Candel’s research advisory board

Candel Therapeutics (NASDAQ: CADL) has announced the appointment of internationally recognized expert in systems immunology and vaccinology, Bali Pulendran, PhD, to Candel’s research advisory board. Dr. Pulendran is the...

October 16, 2025

Developments

Candel achieves primary endpoint in Phase 3 trial evaluating CAN-2409 in prostate cancer

Candel Therapeutics (NASDAQ:CADL) has announced results from its multicenter Phase 3 trial evaluating CAN-2409 viral immunotherapy in patients with localized prostate cancer. The study achieved its primary endpoint...

December 11, 2024

Feature

Candel enhancing cancer patient survival and quality of life with breakthrough viral immunotherapies

Candel Therapeutics (NASDAQ:CADL) is developing off-the-shelf multimodal viral immunotherapies for individualized systemic anti-tumor immune response, specific to the patient’s difficult-to-treat cancer, improving...

June 25, 2024

Tag - CADL

Candel appoints Mark Sims as CCO

Dr. Bali Pulendran joins Candel’s research advisory board

Candel achieves primary endpoint in Phase 3 trial evaluating CAN-2409 in prostate cancer

Candel enhancing cancer patient survival and quality of life with breakthrough viral immunotherapies

Subscribe